Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech.
 
While Onyx Pharmaceuticals (Nasdaq:ONXX) was generally a pretty well-regarded biotech, the news over the weekend that Amgen (Nasdaq:AMNG) had made a bid, and that management was now soliciting higher offers, has sent the shares rocketing up in pre-market trade. Given its solid collection of oncology/hematology assets, it won't be surprising if Onyx draws a crowd to its bargaining table before declaring a winner.

SEE: The Ups And Downs Of Biotechnology
 
Good Reporting Triggers A New Era
Financial Post's Barry Critchley offered quite the scoop late Friday when he reported seeing a letter wherein Amgen made a formal bid for Onyx in the amount of $8.7 billion or $120/share. Onyx ultimately acknowledged the bid, but declared it insufficient and that the company was now going to begin an active sales process. To that end, it's worth noting that Onyx's press release acknowledging Amgen's bid made it clear that the company has received other indications of interest.
 
Who Will Step Up?
Onyx has what almost every pharmaceutical company wants today – a collection of oncology/hematology assets that are of good quality, relatively early in their commercial life-cycle, and likely to offer solid growth in the near term. Accordingly, I don't think Onyx management or investors need to worry about a lack of interest in acquiring this company.
 
Maybe one of the first companies to consider in any auction process is Bayer – the company's OUS partner for Nexavar and Stivarga. I'm skeptical of the potential that Bayer will get involved. Bayer is pretty rigid when it to return on investment and debt targets, and a bid into the $130s or higher would seriously challenge both of those. While Bayer might like to have the other 50% of profits from Nexavar and Stivarga, Bayer has relatively little direct presence (or assets) in the U.S. and would likely need to do further deals to really leverage a new U.S. presence.

SEE: Evaluating Pharmaceutical Companies
 
Amgen certainly has to be a name high on the list of potential acquirers. Biotech M&A has long been a market where “if at first you don't succeed...” is very relevant – just because Onyx management didn't like the initial bid doesn't mean the door is closed to a higher offer. Of all the companies potentially interested in Onyx, Amgen may be among the most motivated – Amgen is trying to build an oncology franchise and is presently quite weak in terms of growth, and Onyx would help both issues.
 
Almost any large pharmaceutical company with a presence in oncology and the US could find some use for Onyx. Novartis (NYSE:NVS), Bristol-Myers (NYSE:BMY), Pfizer (NYSE:PFE) could all fit the bill, and I wouldn't rule out AstraZeneca (NYSE:AZN) which, like Amgen, badly needs near-term growth. I'm also surprised there isn't more initial buzz on Roche (Nasdaq:RHHBY), given the company's huge presence in oncology, its need (arguably) to diversify its oncology assets, and its willingness to pay up for assets.
 
Last, and certainly not least, are some “mid-majors” with solid oncology footing – Celgene (Nasdaq:CELG) and Gilead (Nasdaq:GILD). Both are strong in hematology, which makes me wonder about the extent to which Onyx would really improve the companies' growth profile over the long-term.
 
How High Will The Bidding Go?
Although I think Onyx is probably worth about $110 to $125 on its own, the company will clearly go for more than that in a public sale process. Not only do strategic buyers have the opportunity to take out SG&A expenses and leverage complimentary R&D assets, but a strategic buyer may also be able to enhance the long-term revenue potential of Onyx's marketed drugs and pipeline. As such, I could see the price going above $140 and still offering some value for the right buyer.
 
The Bottom Line
If you don't own Onyx already, this news doesn't really create an investment opportunity. On the other hand, traders may find that trying to play the spread between its open on Monday morning and the eventual deal price is worthwhile. If I were an Onyx shareholder, I'd definitely sit tight – it seems highly improbable to me that the company won't get multiple bids, and I think the odds of the company overplaying its hand such that all of the bidders walk away are relatively low.
 
Disclosure – As of this writing, the author owns shares of Roche.
 
 

Related Articles
  1. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  2. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  3. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  4. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  5. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  6. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  7. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  8. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  9. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  10. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center